Acute myelogenous leukemia (AML) and depression

Depression and anxiety are highly prevalent among patients with Acute myelogenous leukemia (AML), often stemming from the intense stress of a cancer diagnosis, aggressive treatment side effects, and the uncertainty of prognosis. While there is no direct neurological "AML-depression" pathway, the systemic physiological impact of the disease—including chronic fatigue, inflammation, and high-dose steroid use—significantly exacerbates psychological distress.

How does Acute myelogenous leukemia (AML) impact mental health?

Living with Acute myelogenous leukemia (AML) involves traumatic life changes, including prolonged hospitalizations and isolation. Many patients experience "scanxiety" (anxiety surrounding test results) and a sense of loss of control. The physical toll of chemotherapy—such as severe fatigue and pain—can lead to secondary depression, as the body struggles to maintain homeostasis while fighting the malignancy.

What are the signs of depression in Acute myelogenous leukemia (AML) patients?

Recognizing depression in patients with Acute myelogenous leukemia (AML) can be difficult because symptoms often overlap with physical treatment side effects. Look for these specific indicators:

• Persistent feelings of hopelessness or worthlessness regarding the treatment outcome.


• Loss of interest in activities that were previously enjoyable, even when physical energy allows.


• Significant changes in sleep patterns (insomnia or excessive sleeping) not solely explained by medication.


• Social withdrawal from caregivers or family members.


• Difficulty concentrating or "brain fog" that persists beyond the acute phase of treatment.

How is mental health managed in Acute myelogenous leukemia (AML)?

Treatment for mental health in the context of Acute myelogenous leukemia (AML) is multi-faceted. Cognitive Behavioral Therapy (CBT) is highly effective for managing the anxiety of medical procedures, while Acceptance and Commitment Therapy (ACT) helps patients navigate the existential challenges of a serious diagnosis. Pharmacological interventions must be carefully managed by an oncologist and psychiatrist to avoid drug interactions with chemotherapy agents.

Next steps

• Consult your hematologist-oncologist about a referral to an onco-psychologist.


• Join the 62 members in the DiseaseMaps.org community to share experiences with others managing Acute myelogenous leukemia (AML).


• If you are in immediate distress, please contact the 988 Suicide & Crisis Lifeline (in the US) or your local emergency services immediately.

Medical disclaimer: This content is for informational purposes only and does not constitute medical advice, diagnosis, or treatment; always seek the advice of your physician or qualified health provider.

References

• National Cancer Institute (NCI): Psychological Aspects of Cancer


• NIH Genetic and Rare Diseases Information Center (GARD): AML Overview


• American Cancer Society: Managing Cancer-Related Depression


• Leukemia & Lymphoma Society (LLS): Support for Patients and Caregivers